Theravance Biopharma (NASDAQ:TBPH – Get Rating) announced its earnings results on Thursday. The biopharmaceutical company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.06), Fidelity Earnings reports. During the same period in the previous year, the company earned ($0.80) earnings per share.
Theravance Biopharma Price Performance
Shares of TBPH traded down $0.74 during mid-day trading on Friday, hitting $8.74. 1,175,657 shares of the company traded hands, compared to its average volume of 1,883,140. Theravance Biopharma has a one year low of $6.10 and a one year high of $14.28. The business has a 50-day moving average of $8.99 and a 200 day moving average of $9.30.
Wall Street Analysts Forecast Growth
Several research firms have weighed in on TBPH. HC Wainwright reiterated a “buy” rating and set a $12.00 price objective on shares of Theravance Biopharma in a research report on Thursday, July 14th. SVB Leerink initiated coverage on shares of Theravance Biopharma in a report on Monday, May 23rd. They set an “outperform” rating and a $12.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Theravance Biopharma currently has a consensus rating of “Hold” and an average target price of $11.75.
Institutional Trading of Theravance Biopharma
About Theravance Biopharma
Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.
- Get a free copy of the StockNews.com research report on Theravance Biopharma (TBPH)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.